7月3日，uniQure N.V.盘中下跌8.11%，报41.49美元/股，成交额5968.42万美元。股价已跌破此前增发价格45.50美元。
消息面上，公司于6月26日完成约5.69百万股普通股公开发行，发行价45.50美元/股，募资总额约2.59亿美元（含承销商全额行使超额配售权）。此次发行规模从最初计划的1.5亿美元逐步扩大至2.59亿美元，短期内对股本形成显著稀释。募集资金将用于推进核心管线AMT-130及其他研发项目。此前公司因FDA接受基于三年数据提交BLA申请的积极反馈，股价曾大幅走高，当前回调或反映增发后获利盘兑现及稀释压力的释放。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.